Guardant360 CDx is the first FDA-approved comprehensive liquid biopsy with broad Medicare coverage1,2
#1
rated field team, share of voice, and liquid biopsy market share across tumor types3
References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023.
2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test.
August 7, 2020. Updated
August 11, 2020. Accessed April 2, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test
3. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.
12k
covered lives and counting3
ordering oncologist user base3
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma
>300m
